Curatio Therapeutics at a glance
Our mission and base strategy
LMP01 stands poised to redefine the landscape of glioblastoma treatment, offering hope of multi-year survival and enhanced quality of life for those affected by this relentless brain cancer.
LMP02 facilitates the seamless transport of therapeutic entities through the gastrointestinal tract, preserving their structural integrity and bioactivity.
LMP03 represents a promising innovation in osteoarthritis management, addressing the multifaceted challenges associated with this prevalent joint disorder.
LMP04 is an amniotic membrane product that addresses critical medical challenges in diabetic wound healing and corneal regeneration.
A potentially game-changing therapeutic for glioblastoma multiforme that has shown anecdotal evidence in humans of safety, efficacy and multi-year survival with good quality of life in the most aggressive forms of the disease commencing therapy during end stage of disease.
A novel platform for oral administration of DNA/RNA, proteins, biologics, biosimilars and other large molecules.
A first in class disease modifying osteoarthritis drug.
A novel amniotic membrane therapy for diabetic ulcers, pressure ulcers and corneal ulcers.
Our mission and base strategy
